The BIOSECURE Act was passed with a large bipartisan majority in the House in 2024 and now awaits action in the Senate in 2025. Passage of the Act would be a significant first step in protecting ...
Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...
The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...
At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...
Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...
Pharma Sector Multibagger Opportunity - Explore how India could win big in the CDMO space with China-Plus-One strategy, ...
The firm expects WuXi Bio’s order growth might improve given that the “Biosecure Act” bill failed to pass in the U.S. in 2024, the analyst added.
11d
The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...
The Indian pharmaceutical market sees negative volume growth in Q3FY25 but benefits from strong pricing and new product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback